Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
They’re a cure for having an uncontrollable appetite, which makes dieting difficult to impossible.
So if you stop taking them, you retain your controlled appetite?
Spoiler: nope.
They’re not a cure for anything.